However, current treatments are not effective in preventing the occurrence of end-stage renal disease, blindness, disability, and other adverse outcomes, therefore, discovering new therapeutic targets is of utmost importance
This underscores the uncertainty surrounding the long-term effects of these agents, which patients may need to take indefinitely to sustain weight loss
The new label includes references to some of those postmarketing risks, including intestinal obstruction, [and] severe constipation including fecal impaction. Some patients who took Zepbound have filed lawsuits, accusing Eli Lilly of failing to properly warn them that Zepbound could increase their risk of severe gut problems, including bowel obstructions, pancreatitis, and gastroparesis
There was no difference in disability (limitation of activities due to fibromyalgia)
lab-marker issues are managed by monitoring and, if needed, a pause